Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease  by Jädert, Cecilia et al.
Research Paper
Preventive and therapeutic effects of nitrite supplementation
in experimental inﬂammatory bowel disease$,$$
Cecilia Jädert a, Mia Phillipson b, Lena Holm b, Jon O. Lundberg a, Sara Borniquel a,n
a Department of Pharmacology and Physiology, Karolinska Institute, Sweden
b Department of Medical Cell Biology, Uppsala University, Sweden
a r t i c l e i n f o
Article history:
Received 9 December 2013
Received in revised form
16 December 2013
Accepted 16 December 2013







a b s t r a c t
Background: Inorganic nitrate and nitrite have emerged as alternative substrates for nitric oxide (NO)
generation in the gastrointestinal tract, and have shown to be protective against drug-induced gastric
injury. The aim of this study was to investigate the preventive and therapeutic effects of nitrate and
nitrite in a model of experimental colitis.
Methods: Colitis was induced in mice by administrating dextran sulfate sodium (DSS) with concurrent
administration of nitrite (1 mM) or nitrate (10 mM) in the drinking water for 7 days. A therapeutic
approach was also investigated by initiating nitrite treatment 3 days after DSS-induced colitis. Clinical
and inﬂammatory markers were assessed and the colonic mucus thickness was measured in vivo. The
effect of nitrite on wound healing was evaluated using colon epithelial cells.
Results: Concurrent administration of DSS and nitrite (1 mM) alleviated inﬂammation as determined by
reduced disease activity index score (DAI) and increased colon length, while nitrate (10 mM) only
reduced the DAI-score. Nitrite also displayed therapeutic effects by ameliorating established colonic
inﬂammation with reduced colonic expression of iNOS and improving histopathology. DSS-induced
decrease in colonic mucus thickness was completely prevented by nitrite administration. In addition,
goblet cell abundance was lower by DSS treatment, but was increased by addition of nitrite. Further
studies using colon epithelial cells revealed an NO-dependent improvement in wound healing with
nitrite administration.
Conclusion: Nitrite exerts both preventive and therapeutic effects in colonic inﬂammation. The protective
effects involve preservation of an intact adherent mucus layer and regulation of epithelial cell restitution.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Ulcerative colitis (UC) and Crohn0s disease are collectively
included in the chronic intestinal disorders of inﬂammatory bowel
diseases (IBDs). The etiology of these diseases remains unknown
but the cause is probably multifaceted involving an inappropriate
immune response, change in gut microbiota and individual genetic
predisposition [1,2]. A key feature of IBD is the disruption of the
protective mucosal barrier, with epithelial damage and a destroyed
mucus layer. These changes might result in bacterial penetration of
the mucosal barrier, resulting in uncontrolled mucosal inﬂamma-
tion [3–5].
The most widely used experimental model of IBD is adminis-
tration of dextran sulfate sodium (DSS) in the drinking water.
Colitis is typically induced in mice by administrating 3–5% (DSS)
for 5–7 days, and this model exhibits pathophysiological features
that resemble human UC [6,7]. The mechanism of DSS-induced
colonic mucosal inﬂammation is not completely understood.
However, recent results indicate that the DSS molecule destabi-
lizes the structure and barrier function of the mucus layer [8]
and also exerts a direct toxic effect on the epithelial cells with
subsequent inﬁltration of immune cells [6,9].
To protect the colonic mucosa from bacterial inﬁltration, the
epithelium is covered by secreted mucus in a two-layer system.
The outer loosely adherent layer can be removed by suction while
the inner ﬁrmly adherent layer is strongly attached to the
epithelial cells [10]. In a healthy situation, the outer loosely
adherent mucus layer is colonized with commensal bacteria while
the inner ﬁrmly adherent mucus layer contain substantially fewer
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bacteria, forming the functional barrier between bacteria and the
epithelium [11,12]. Muc2, the major gel-forming and protective
mucin in the mucus layers, is a large glycoprotein secreted by the
colonic goblet cells [12–14]. The loosely adherent mucus layer is
formed by regulated protease degradation of the Muc2 mucus gel
forming the inner mucus layer, which is maintained at a relatively
constant thickness [12]. Secretion of Muc2 mucins is crucial for the
protection of the colonic mucosa, as shown in Muc2/ mice,
which lack the protective mucus layer. These mice develop
spontaneous colitis and colon cancer with increasing age, and
are also more susceptible to pathogens and DSS-induced colitis
[8,14–16]. Moreover, patients with UC and animal models of
experimental colitis demonstrate a thinner mucus layer with
increased permeability, allowing bacteria to get in direct contact
with the colonic mucosa [4,8]. Thus, it is suggested that an intact
inner adherent mucus layer is an important factor to prevent
activation of inﬂammatory reactions by bacteria [14].
Endogenous production of nitric oxide (NO) by the nitric oxide
synthases (NOSs) is essential for physiological regulation of
gastrointestinal function [17], and NO also plays a role during
inﬂammatory conditions such as IBD and in DSS-induced colitis
[18,19]. In addition to the NOSs, an alternative pathway for NO
generation in mammals has been described [20,21], involving
sequential reduction of dietary-derived nitrate and nitrite [17].
Vegetables, in particular green leafy plants, contain high amounts
of nitrate which is efﬁciently absorbed in the gastrointestinal tract
[22]. About 25% of the systemic circulating nitrate is accumulated
in the salivary glands [23,24]. Salivary nitrate is then converted
into nitrite by efﬁcient oral commensal bacteria [25,26], resulting
in high concentrations of salivary nitrite [27]. When swallowed
into the acidic environment of the stomach, a part of the salivary-
derived nitrite is protonated and converted to nitric oxide (NO)
and other nitrogen oxides including S-nitrosothiols [20]. In addi-
tion, a signiﬁcant share of the nitrite escapes gastric passage and
enters the systemic circulation and tissues where it can be further
metabolized to NO and other bioactive nitrogen oxides [27,28].
A part of the dietary nitrate and nitrite may also proceed into
the small intestine and cecum where it can be absorbed or fur-
ther utilized by bacteria to produce NO [29]. It is believed that
nitrate and nitrite are absorbed or consumed before reaching the
colon [29].
Dietary nitrate and nitrite have been shown to increase gastric
mucus formation and blood ﬂow and to protect the mucosa
against NSAID-induced injury [25,30–32]. Recently it was also
demonstrated that the mucus thickness in colon was decreased
after DSS-induced colitis in mice [8] and that high pharmacologi-
cal doses of nitrite can attenuate experimental colitis [33]. In this
study, we investigated potential preventive and therapeutic effects
of nitrate and nitrite in experimental colitis and the potential role
of nitrite in regulation of colonic mucosal integrity. Furthermore,




Female BALB/c mice (Scanbur AB, Sollentuna, Sweden),
7–8 week old and weighing 20–22 g, were housed under tempera-
ture- and humidity-controlled conditions with 12-h-light/-dark cycles
and with at least 7-d of local acclimatization before starting experi-
ments. Mice were fed a standard pellet diet (R36, Lantmännen,
Kimstad, Sweden) and tap water ad libitum. All experimental work
on mice was approved by the Ethics Committee for Animal Experi-
ments at the Karolinska Institute and at Uppsala University.
Experimental procedures
Experimental colitis was induced in mice by administrating 2%
or 2.5% DSS (45 kDa, TdB Consultancy, Uppsala, Sweden) in the
drinking water for 7 d. Sodium nitrite (NaNO2 , 1 mM) (Sigma, St
Louis, MO, USA) or sodium nitrate (NaNO3 , 10 mM) (Sigma, St
Louis, MO, USA) were also administered in the drinking water. The
doses of nitrate and nitrite were chosen to represent a dose readily
achievable via the diet (in particular from green leafy vegetables),
and compensating for the different pharmacokinetics between
mice and humans [31,34]. In particular, the accumulation of nitrate
and nitrite in saliva is considerably greater in humans [35],
gradients which are not observed in rodents. Mice were randomly
divided into 4 groups: control, DSS, DSSþnitrite and DSSþnitrate.
In a ﬁrst set of experiments, nitrate or nitrite supplementation was
initiated simultaneously with 2% DSS administration (Fig. 1A). In
the other experimental setup, nitrite supplementation was started
3 d after initiating administration of 2.5% DSS (Fig. 1B), this to
slightly increase the severity of the colitis. Control mice received
tap water only. The mice were weighed daily and visually
inspected for diarrhea and rectal bleeding. At day 7, the Disease
Activity Index (DAI) was evaluated as previously described [36].
The mice were anesthetized with isoﬂurane (Forenes, Abbott
Scandinavia AB, Solna, Sweden) and blood was collected by heart
puncture, followed by cervical dislocation. The colon was removed
and its length was measured. Tissues and plasma samples were
frozen and kept at 80 1C until further analysis.
Animal preparation for colonic mucus thickness measurements
Mice pretreated with 2.5% DSS and nitrite (Fig. 1B) were
anesthetized by inhalation of 2.4% isoﬂurane (Forenes, Abbott
Scandinavia AB, Solna, Sweden) in a mixture of air and oxygen (total
oxygen 40%) through a breathing mask. Body temperature was
maintained by a heating pad underneath the animal during the
experimental procedure. The colonic preparation for investigation
Fig. 1. Experimental protocol for DSS-induced colitis in mice. Experimental colitis
was induced in mice by administrating 2–2.5% DSS in drinking water ad libtum for
7 d. Sodium nitrite (1 mM) or sodium nitrate (10 mM) was administered orally in
drinking water in combination with DSS. (A) In the preventive experimental setup,
nitrate or nitrite was supplemented simultaneously with DSS, and (B) in the
therapeutic approach, nitrite was added 3 d after DSS administration.
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of the mucus thickness by intravital microscopy has been described
extensively elsewhere [8,37]. Prior to thickness measurements of
the ﬁrmly adherent mucus, the luminal loosely adherent mucus
layer was removed by gentle suction with a thin polyethylene
cannula connected to a syringe. This procedure was conducted
under supervision through a stereomicroscope to avoid contact
with the epithelium. Five different spots in the adherent mucus
were chosen and measured after the ﬁrst suction. The mucosa
preparation was allowed to recover during 1 h before a second
removal of the loosely adherent mucus by suction, followed by
repeated measurements of the same ﬁve spots in the adherent
mucus layer. Inconsistent values from the same spot of the two
separate measurements were excluded to only attain results of a
physiological functional mucosa. Mean values from the different
spots at the two independent measurements were used as one
observation.
Immunohistochemistry
Immunohistochemical staining of frozen colon sections was
performed as previously described [38] to asses levels of inducible
NO synthase (iNOS), NFκB p65 (Santa Cruz Biotechnology, CA,
USA) and mucin 2 (Muc2) (Abcam, Cambridge, UK). Secondary
antibodies were biotinylated anti-mouse and anti-rabbit IgG
(Jackson Immunoresearch Laboratories, PA, USA). The avidin bio-
tinylated enzyme complex (Vectastain ABC kit, Vector Labora-
tories, Burlingame, CA, USA) and 3,3-diaminobenzidine were used
to detect the antibody. Quantiﬁcation of stained sections was done
by an investigator blinded to the protocol.
Histological assessment
The colon was removed from mice and ﬁxed in 10% parafor-
maldehyde by submersion. After 24 h the tissue samples were
transferred to 70% ethanol before routine processing and parafﬁn
embedding. Sections were cut at 4 mm thickness on a rotary
microtome. Consecutive sections were stained according to stan-
dard protocols [39] with hematoxylin and eosin (H&E), and with
alcian blue–periodic acid-Schiff (PAS) reagent to visualize neutral
and acidic colonic mucin. Histological analysis was performed by
an investigator blinded to the protocol. The severity of the disease
was graded in the H&E-stained sections on a scale from 0 to 3 by
the sum of the scores of epithelial cell damage, crypt destruction
and inﬁltration of inﬂammatory cells, as previously described [7].
The abundance of goblet cells (mucin) was separately evaluated in
the alcian blue–PAS-stained sections, according to previously
described protocol [40]. Colon epithelial cell wound repair assay:
The human colonocyte cell line SW480 was maintained in DMEM
supplemented with 1% penicillin/streptomycin and 10% FBS in a
humidiﬁed incubator at 37 1C and 0.5% CO2. Cells were grown to
conﬂuence in six-well plates, and a straight incision was made on
the monolayer using a sterile pipette tip. Nitrite (Sigma, St Louis,
MO, USA) (1 mM–1 mM) and 2-(4-Carboxyphenyl)-4,4,5,5-tetra-
methylimidazoline-1-oxyl-3-oxide (cPTIO) (Cayman, Ann Arbor,
MI, USA) (100 mM) treatment was initiated after wound incision.
The administration of the inhibitor was performed 1 h before the
treatment with nitrite. Wound closure was monitored by micro-
scopy (Axiovert 40 CFL, Zeiss), and the distance of cell healing was
measured at 24 h compared to the initial wound area, quantiﬁed
using NIH ImageJ software. Each experiment was repeated three
times and treatments were performed in duplicates, each well was
measured at 3 independent positions which were calculated to a
mean of distance.
Statistical analysis
Data are presented as mean7SEM. Statistical analysis was
performed using 1-way ANOVA with Tukey0s post hoc test.
Differences of Po0.05 were considered signiﬁcant using GraphPad
Prism 5.02 (Graph Pad Software, San Diego, CA, USA).
Results
Nitrate and nitrite supplementation attenuates DSS-induced colitis in
mice
Shortening of the colon is a distinctive hallmark of colon
inﬂammation in rodents [41]. Administration of 2% DSS for 7 days
caused a 30% reduction of colon length compared with the control
group (Fig. 2A), and concurrent supplementation with nitrite
reduced the colon shortening. Furthermore, DSS administration
signiﬁcantly increased the DAI-score while nitrite supplementa-
tion mediated a 70% lower score compared with the DSS-group
(Fig. 2B). Nitrate supplementation did not affect colon length
after DSS administration, however, the DAI-score was reduced
(Supplemental Fig. S1A and B). Further anti-inﬂammatory effects
of nitrate were demonstrated by lower colonic expression of iNOS
and the NF-κB subunit p65 (Supplemental Fig. S1C–F). No differ-
ences in water consumption between the groups were observed
(Supplemental Fig. S2A and B).
Therapeutic effects of nitrite supplementation
To explore whether nitrite has a therapeutic effect on an
already established inﬂammation, mice were treated with 2.5%
DSS during 3 d before nitrite administration (Fig. 1B). The time
point for onset of nitrite supplementation was chosen based on
Fig. 2. Preventive effects of nitrite with concurrent DSS administration. (A) Colon
length and (B) disease activity index (DAI) in untreated mice (n¼29) and those
treated with 2% DSS (n¼28) or mice with DSSþnitrite supplementation (1 mM)
(n¼27), measured at 7 d after treatment (Po0.05, n vs. control, # vs. DSS-group).
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initial observation of sickness onset (data not shown). Adminis-
tration of 2.5% DSS for 7 days mediated a reduction in colon length
and increased DAI-score (Fig. 3A and B). Nitrite supplementation
started once colitis was initiated (day3), demonstrated a protective
effect with a reduced colon shortening compared to the DSS-group
at day 7. Further, the DAI-score was reduced with 60% compared
with the DSS-treated mice. Investigation of the anti-inﬂammatory
effects demonstrated an increased colonic expression of iNOS after
DSS treatment, which was completely prevented by nitrite (Fig. 4A
and B). Microscopic examination of H&E stained colonic sections
revealed signiﬁcant histopathological injuries (including colon
crypt loss, immune cell inﬂux, and ulceration of the epithelial
surface) in DSS-treated mice compared to controls (Fig. 4C and D).
Nitrite supplementation initiated when the colonic inﬂammation
was already established strongly reduced the clinical symptoms as
well as markers of colonic inﬂammation. No differences in water
consumption between the groups were observed (Supplemental
Fig. S2C).
Nitrite supplementation increases the adherent colonic mucus layer
after DSS treatment
Since the colonic mucus layer has an important barrier function
protecting from invading bacteria [4,12] and is reduced with DSS
administration [8], we next investigated the effect of nitrite on the
adherent colonic mucus layer with DSS-induced colitis. The ﬁrmly
adherent mucus layer was signiﬁcantly thinner after treatment
with 2.5% DSS for 7 days compared with control mice (3871 and
4271 mm, respectively, Fig. 5A). Nitrite supplementation starting
day 3 after induction of colitis prevented the decrease in mucus
thickness, and maintained the thickness at the same levels as
control animals (4371 mm). In addition, the goblet cells in the
colonic mucosa were quantiﬁed. The abundance of goblet cells was
decreased in DSS-treated mice compared with control group
(Fig. 5B and C), while nitrite supplementation had a protective
effect on goblet cells. In contrast, an increased Muc2-expression in
colon tissue was observed with DSS-treatment (Fig. 5D), while
nitrite supplementation indicated a trend towards lower Muc2-
expression in the disease group.
Nitrite promotes colon epithelial cell wound healing
One proposed mechanism of DSS-induced colonic injury is
direct epithelial cell injury with increased apoptosis and erosions
with subsequent breakdown of the epithelial barrier function
[7,9]. We therefore assessed the effect of sodium nitrite (1 mM–
1 mM) on colonic epithelial wound repair in vitro. Increased
healing 24 h after a mechanically made incision in conﬂuent
monolayers of SW480 cells was observed with 100 mM nitrite
compared to untreated cells (Fig. 6A). To further explore whether
the effects of improved epithelial healing was due to NO forma-
tion, the cells were pretreated with the NO scavenger cPTIO
(100 mM) before initiation of nitrite treatment (10 and 100 mM).
The protective effect of increased healing with nitrite was lost in
the presence of cPTIO, and cPTIO alone did not have any effect on
wound healing (Fig. 6B).
Discussion
Although the precise etiology of UC still is unknown, an intact
barrier function with the colonic epithelium and a protective
mucus layer are crucial to avoid aggravation of the disease [4,5].
We now demonstrate that supplementation with sodium nitrite
alleviates colitis in mice, both as preventive and therapeutic
regiments. The protective effects by nitrite in the therapeutic
approach involve a restored thickness of the colonic ﬁrmly
adherent mucus layer demonstrated in vivo, and in vitro observa-
tions of increased healing of colon epithelial cells. These results
provide important insights of the therapeutic effect by nitrite on
already initiated colonic inﬂammation.
Nitrite and nitrate originating from dietary sources are impor-
tant alternative substrates for NO formation and complement the
endogenous production by the NOS pathway [17]. Nitrogen oxides
have over the last decade been discovered to perform important
effects on gastrointestinal integrity [42,43]. Björne et al. [31]
demonstrated that human salivary nitrite, collected after a dietary
nitrate load, could increase rat gastric mucus generation and
mucosal blood ﬂow. Also, dietary nitrate has been shown to
increase gastric mucus thickness and mucosal blood ﬂow, thereby
inducing protection against NSAID-induced injury [25,30].
However, the effect on colonic mucosal integrity is less well
studied. In order to investigate the effects of nitrite supplementa-
tion on colonic injury, the widespread model of DSS-induced
colitis was used. The classical signs of tissue damage with
continuous DSS-treatment can be seen by increased crypt disrup-
tion, inﬁltration of inﬂammatory cells, weight loss, colon short-
ening and rectal bleeding [7,44]. In our study, we chose to use 2–
2.5% of DSS in order to induce mild colitis and be able to study the
anti-inﬂammatory effects of a dietary supplementation with
sodium nitrite [45]. Even with this relatively low dose of DSS,
robust increases in DAI score and reduction in colon length were
seen after 7 days. Simultaneous supplementation with nitrite
resulted in lower DAI score and an increased colon length
compared to the disease group. Administration of nitrate also
revealed some anti-inﬂammatory effects, with lower DAI-score
and reduced expression of colonic iNOS and p65 after DSS-
administration. However, no effect was seen on the length of the
colon. The reasons for the discrepancy between nitrate and nitrite
Fig. 3. Therapeutic effects of delayed nitrite supplementation after DSS adminis-
tration. (A) Colon length and (B) disease activity index (DAI) in untreated mice and
those treated with 2.5% DSS or with DSSþnitrite supplementation (1 mM),
measured at 7 d after treatment (Po0.01, n vs. control, # vs. DSS-group).
C. Jädert et al. / Redox Biology 2 (2014) 73–8176
treatment are unclear but could be related to differences in
pharmacokinetics, with nitrite giving sharper and shorter nitrite
peaks in plasma and nitrate resulting in modest but sustained
nitrite increases. However, a single measurement of nitrite after
the 7 days of treatment did not reveal any signiﬁcant differences in
plasma nitrite between the different treatments (data not shown).
Fig. 4. Nitrite attenuates DSS-induced colonic inﬂammation. (A) Representative pictures of colonic iNOS expression by immunohistochemical staining, and (B) quantiﬁcation
of iNOS staining (a.u.) (n¼10 in each individual group). (C) Representative histology pictures with hematoxylin and eosin staining (scale bar 10 mm) and (D) summary of the
colonic histology score (n¼8 in each individual group) (Po0.05, n vs. control, # vs. DSS-group).
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Since nitrite supplementation demonstrated stronger clinical anti-
inﬂammatory results, we decided to continue with this supplementa-
tion for further experiments. Our results are in line with other recent
studies showing anti-inﬂammatory effects of nitrite administration
[33,46], and suggest that nitrite and to some extent dietary nitrate, can
attenuate acute inﬂammation in experimental colitis.
The few studies published looking at anti-inﬂammatory effects of
nitrite and nitrate have been designed in a preventive manner; thus
Fig. 5. Analysis of colonic mucus thickness and goblet cell abundance with nitrite supplementation. (A) Firmly adherent mucus thickness (μm) in untreated mice (n¼6),
DSS-treated mice (n¼5) and mice with DSSþnitrite supplementation (n¼5). (B) Representative pictures of histological colon samples stained with Periodic Acid Schiff/
Alcian Blue (PAS/AB) (scale bar 50 mm) and (C) quantiﬁcation of the number of goblet cells in colon samples of untreated mice, DSS-treated mice and mice with DSSþnitrite
supplementation (n¼8 in each individual group). (D) Quantiﬁcation (a.u.) of colonic Muc2 expression by immunohistochemistry staining (n¼10 in each individual group)
(Po0.05, n vs. control, # vs. DSS-group).
Fig. 6. Colon epithelial cell wound healing with nitrite. (A) SW480 colon epithelial cells were treated with varying concentrations of sodium nitrite (1 mM–1 mM), and
(B) with or without cPTIO (100 mM) after wound incision. Healing was measured after 24 h and expressed as healing vs. 0 h (%) (Po0.01, n vs. untreated, # vs. Nitrite
100 mM).
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the administration was initiated before or simultaneously as the
inﬂammatory agent [33,46]. In order to also study the therapeutic
effects, we initiated DSS-administration before the onset of nitrite
supplementation. Common clinical symptoms of DSS-treated mice
were observed, such as rectal bleeding and diarrhea, which have
shown good correlation to the inﬂammatory status in the acute phase
of colitis [47]. It has beenwell described that histological changes with
inﬂammation and clinical signs of colitis are present at day 3 of DSS-
administration [7]. Similar observations on clinical status were made
with mice in our study (data not shown), therefore administration of
nitrite was initiated at day 3. Interestingly, even with this delay in
nitrite supplementation a strongly reduced DAI score as well as
improvements of colon shortening was seen. Both the preventive
and the therapeutic approach of nitrite supplementation indicated
similar clinical results, demonstrating a strong protective effect of
nitrite even on established disease. This was further conﬁrmed by
closer investigations of the inﬂammatory status in colonic tissue,
which indicated a reduced colonic expression of iNOS and lower
histopathological scores in nitrite-supplemented mice. Othake et al.
[33] have previously shown protective effects of nitrite, where the
treatment was initiated before the onset of DSS-induced colitis.
However, our results demonstrate that nitrite also have therapeutic
effects with a much lower dose than previously studied, which is
clearly closer to what is achieved from a normal diet. Other studies
demonstrating anti-inﬂammatory effects of dietary nitrate and nitrite
are emerging in different experimental inﬂammatory diseases, e.g. by
reducing vascular pathology [43]. Dietary nitrite supplementation has
been demonstrated to prevent inﬂammation induced by hypercholes-
terolemia, with reduced leukocyte adhesion and emigration [46].
In line with these results, we have recently shown that also dietary
nitrate prevents leukocyte activation in acute microvascular inﬂam-
mation, and further reduces expression of P-selectin leukocyte inﬁl-
tration in small-intestinal tissue with NSAID-injury [48]. Moreover,
Carlström et al. [49] recently demonstrated potent anti-inﬂammatory
and antioxidant effects of dietary nitrate in a rat model of chronic
hypertension with concomitant renal and cardiac inﬂammation.
Inﬂammatory responses with enhanced leukocyte and platelet aggre-
gation, leading to defects in the microcirculation have been postulated
to play a central pathogenic role in development of IBD and in DSS-
induced colitis [50,51]. Our observation is in line with these previous
studies, suggesting that oral therapeutic nitrite supplementation may
inﬂuence the inﬂammatory response. A reduced immune cell inﬁltra-
tion was seen on the histological sections of colons after DSS-
administration, as well as lower levels of iNOS, indicating a systemic
effect of oral nitrite supplementation on immune cell activation.
An altered colonic mucus layer is prominent in patients with UC
and in DSS-treated mice [4,8,52,53]. Furthermore, it has been
indicated that bacteria may penetrate the inner mucus layer in
patients with UC and in several different animal models of experi-
mental bowel disease [4,11,12,53,54]. This demonstrates the impor-
tance of an intact mucus layer for protection against bacterial-
induced inﬂammation. In agreement with previous results, our
studies show a reduced thickness of the adherent mucus layer after
DSS-induced colitis [8]. Interestingly, nitrite supplementation nor-
malized the colonic adherent mucus thickness to similar levels as
the control group. In addition to our results showing lower inﬂam-
matory status after nitrite supplementation, this data suggest a
potential therapeutic approach that may increase the mucus barrier
to prevent bacterial penetration and maintain colon homeostasis.
Goblet cell depletion is another morphological characteristic to
assess disease activity in experimental colitis and UC, since these
cells produce and release the major colonic mucin, Muc2 [55,56].
Our results of increased mucus thickness with nitrite supplementa-
tion corresponded to an induced abundance of goblet cells in the
colonic mucosa compared to DSS-treatment alone. This might
indicate a direct effect of nitrite on mucus production and release.
Despite this preservation of goblet cells by nitrite, the opposite
result was surprisingly seen in colonic stainings of Muc2. As
DSS-administration degraded mucus thickness and lowered the
abundance of goblet cells, Muc2 expression was increased. The
reason for this can only be speculated upon at this stage. In this
setting, the production of Muc2 per goblet cell might be enhanced to
compensate for the loss of colonic mucus. In accordance with our
ﬁndings, Renes et al. [57] demonstrated a decreased number of
goblet cells during DSS colitis in rats, with maintained and even
increased Muc2 synthesis and total Muc2 secretion. Further studies
are needed to investigate the regulatory mechanism of nitrite- and
NO-mediated mucus secretion.
The initial damage of DSS is loss of crypts and thinning of the
epithelium, without obvious signs of inﬂammation. Only later
stages of DSS-induced colitis involve inﬁltration of inﬂammatory
cells [7]. Therefore, by maintaining epithelial cell homeostasis in
the initial state of disease, the onset of an inﬂammatory response
might be reduced and thereby alleviate the severity of the disease.
Our in vitro studies clearly show that nitrite can improve colon
epithelial cell healing of a disrupted cell layer. These results are in
line with modern treatment strategies for UC where stimulation of
mucosal healing has attained increased attention among clinicians
and is emerging as an important therapeutic endpoint in clinical
trials of IBD [5]. There is growing evidence that mucosal healing is
important to predict probability of disease relapse, risk of a future
colectomy and of colorectal cancer development [2,5,58]. Thus,
therapies with the ability to improve epithelial restitution of mild-
to-moderate UC can have a signiﬁcant impact on the quality of life
of affected persons [58]. In agreement with our results, Wang et al.
[59] recently showed that sodium nitrite enhances cell prolifera-
tion and wound healing of human airway epithelial cells, at similar
concentrations of nitrite. The fact that cPTIO inhibited nitrite-
induced wound healing suggests an important role of NO in these
cells, an effect also observed by Wang et al. and by earlier studies
on airway cells [60]. Although NO is a likely mediator of the
observed effects, one should note that cPTIO also scavenges NO2
[61], another bioactive radical that might be formed from nitrite.
More studies on the effect of nitrite in other inﬂammatory models
of colitis, e.g. genetically modiﬁed or by cell transfer, are crucial to
evaluate if these pre-clinical data have potential to translate into a
new clinically effective agent [62].
In the present study, we demonstrate that dietary nitrite
supplementation signiﬁcantly alleviates DSS-induced colitis using
both preventive and therapeutic approaches. A likely mechanism
of protection by nitrite is NO-dependent improvement of the
colonic mucosal integrity. This includes effects on the colonic
epithelium, as revealed by less epithelial cell damage and crypt
destruction in histology sections after DSS-administration and
increased epithelial cell wound healing. Furthermore, nitrite
supplementation during DSS-colitis resulted in a maintained
thickness of the colonic adherent mucus layer, as well as increased
abundance of mucus generating goblet cells. Further studies will
reveal if this novel approach could lead to new dietary recom-
mendations and approaches for therapy of IBD.
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